Preclinical In-vivo Imaging Market Overview
Preclinical imaging is the visualization of living animals for research purposes, such as drug development. Imaging modalities are very crucial for researchers in observing changes, either at the organ, tissue, cell, or molecular level, responding to physiological or environmental changes. Imaging modalities that are non-invasive and in-vivo is important to study animal models longitudinally. Techniques such as high-frequency micro-ultrasound, magnetic resonance imaging (MRI) and computed tomography (CT) are usually used for anatomical imaging, while optical imaging (fluorescence and bioluminescence), positron emission tomography (PET), and single photon emission computed tomography (SPECT) are usually used for molecular visualizations. Pre-clinical in-vivo imaging industry has experienced myriad technological advancements, changes in market due to industry consolidation, and change in government funding and support for research studies across the global over the past decade.
Globally, factors such as technological advancements in molecular imaging modalities, growing acceptance of preclinical imaging as a legitimate drug development tool, are fueling the demand of preclinical imaging systems and reagents. Declining NIH budgets for medical science research studies and high implementation cost of sophisticated preclinical imaging systems are restricting the growth of the global preclinical imaging market.
Preclinical In-vivo Imaging Market Forecast Report (2018-2023)
The Global Preclinical in-vivo imaging market has been estimated at USD 714.17 Million in 2018 and is projected to reach USD 944.95 Million by 2023, at a CAGR of 5.76% during the forecast period from 2018 to 2023.
Preclinical In-vivo Imaging Market Segmentation
Global market for Preclinical In-vivo Imaging is segmented based on Modality and Reagents. Based on modality, the global preclinical imaging market is divided into seven major segments, namely, optical imaging, nuclear imaging, micro-MRI, micro-CT, micro-ultrasound, photoacoustic, and magnetic particle imaging systems. The preclinical optical imaging systems market includes bioluminescence/fluorescence imaging systems, standalone fluorescence imaging systems, optical + X-ray/optical + CT imaging systems. The preclinical nuclear imaging systems market comprises micro-PET systems (standalone PET, PET/CT, and PET/MRI), micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI), and tri-modality (PET/SPECT/CT) imaging systems. Bases on the reagents, the global preclinical imaging market is divided into five segments, namely, optical imaging reagents, nuclear imaging reagents, MRI contrast agents, ultrasound contrast agents, and CT contrast agents. The optical imaging reagents market is further sub-segmented as bioluminescent and fluorescent imaging reagents. Likewise, the nuclear imaging reagents market is divided as preclinical PET tracers and SPECT probes.
Geographical Analysis
Geographically Global market for Preclinical In-vivo Imaging is segmented into North America, Asia Pacific, Latin America, Europe, and Africa & Middle-East. North America holds the largest share of the global preclinical imaging market, followed by Europe. Factors including rising R&D activities by big pharma and biotech companies in developing nations and increased government funding for development of pharmaceutical industry are stimulating the growth of the preclinical imaging market in the Asia-Pacific region.,
are the key players operating in the global pre-clinical imaging systems market
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Modality
5.1.1 Optical imaging
5.1.1.1 Bioluminescence/fluorescence imaging systems
5.1.1.2 Standalone fluorescence imaging systems
5.1.1.3 Optical + X-ray/optical + CT imaging systems
5.1.2 Nuclear imaging
5.1.2.1 Micro-PET systems (standalone PET, PET/CT, and PET/MRI)
5.1.2.2 Micro-SPECT systems (standalone SPECT, SPECT/CT, and SPECT/MRI)
5.1.2.3 Tri-modality (PET/SPECT/CT) imaging systems
5.1.3 Micro-MRI
5.1.4 Micro-CT
5.1.5 Micro-ultrasound
5.1.6 Photoacoustic
5.1.7 Magnetic particle imaging systems
5.2 By Reagent
5.2.1 Optical imaging reagents
5.2.1.1 Bioluminescent reagents
5.2.1.2 Fluorescent imaging reagents
5.2.2 Nuclear imaging reagents
5.2.2.1 Preclinical PET tracers
5.2.2.2 Preclinical SPECT probes
5.2.3 MRI contrast agents
5.2.4 Ultrasound contrast agents
5.2.5 CT contrast agents
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Aspect Imaging
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Biospace Lab S.A.
8.3 Bruker Corporation
8.4 LI-COR Biosciences
8.5 Mediso Ltd.
8.6 MILabs B.V.
8.7 MR Solutions Ltd
8.8 PerkinElmer
8.9 TriFoil Imaging
8.10 FUJIFILM VisualSonics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
